Drugs / Arterakine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02788864 Comparator | May → Nov 2016 | malaria | Oxford University Clinical Research Unit, Vietnam | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Arterakine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02788864 ↗ |
| Known as | DHA/piperaquine | “Active drug: Arterakine (DHA/piperaquine) one tablet contains 40 mg of dihydroartemisinin and 320 mg piperaquine.” NCT02788864 ↗ |